Company intelligence / Profile preview
Werewolf Therapeutics, Inc.
Watertown, Massachusetts, United Stateswerewolftx.com ↗
- Ownership
- Public · HOWL
- Development stage
- Phase 1
01
Overview
WTX-124 (IL-2 INDUKINE) has shown promising durable anti-tumor activity with unprecedented tolerability for cytokine therapeutics in Phase 1/1b trials. WTX-330 (IL-12 INDUKINE) is advancing to Phase 1/2 trials in Q1 2025. Both programs have demonstrated improved therapeutic index compared to traditional cytokine therapies.
- Therapeutic areas
- GastroenterologyOncology
- Modalities
- Conditionally activated biologicsINDUKINE™ molecules (engineered cytokines)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Financials
- Market cap
- $49.6M
- Total revenue
- $0
- Enterprise value
- $27.6M
Beyond the preview
Go deeper on Werewolf Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Werewolf Therapeutics, Inc..